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and KOL reviewers can be found at: http://
scholarlykitchen.sspnet.org/2012/04/10/
emergence-of-a-citation-cartel
A case in point is a review of interleukin-2 
(IL-2) that I was asked to review recently. 
After reading the manuscript, before agree-
ing to undertake the review, I told the editor 
who contacted me that I felt that there were 
numerous instances where the authors were 
selective in their choice of references, favor-
ing their own work over those of others, 
and that I felt that the review needed major 
revisions. The journalist-editor assured me 
that he was extremely interested in my opin-
ion, even so. Moreover, he also wanted the 
review within 7 days, because the journal 
wanted to include the review in their next 
issue, which was going to press very soon.
Scholarship in science is made easier 
than other fields because there is a written 
record of articles that allows the writer, the 
journal reviewer, and the reader to verify 
statements in any article by referring to 
the original publication. In this particular 
instance, I called attention to the very first 
sentence of the manuscript, which stated:
“Interleukin-2 (IL-2) was first discovered 
over 35 years ago as an activity present in 
supernatants of activated human T cells 
that mediates T cell growth and prolifera-
tion (Morgan et al., 1976).”
This statement belies the fact that IL-2 is 
a molecule, not simply “an activity in super-
natants.” Therefore, I asked the editors and 
the authors to read this particular report, 
because this publication, although impor-
tant in the history of immunology, makes 
no reference to IL-2 or even to T cell growth 
factor (TCGF). Instead, this article reports 
that Lymphocyte Conditioned Media (Ly-
CM) can be used to maintain the prolifera-
tion of T cells derived from human bone 
marrow for as long as 13-weeks. By referring 
to this report as the original description of 
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Review articles by experts in a field are highly 
sought after by traditional for-profit pub-
lishers because they serve to draw readers 
and subscribers to their journal. Also, inves-
tigators covet invitations from prestigious 
journals to write review articles, because 
they bring widespread respect and admi-
ration to the individual as one of the “Key 
Opinion Leaders” (KOL). This cachet has 
evolved into a mutual interdependence of 
the KOLs and the prestigious journals. This 
mutual relationship is codified and meas-
ured by the Impact Factor of the journal, 
in that reviews receive many more citations 
than do other types of articles, including 
original research articles, because scientists 
cite them more often than original research 
articles. A well-researched review article is 
invaluable because it is assumed that one 
can rely on a particular reviewer to be cor-
rect in the details of a particular subject.
However, there is a “dark side” to the 
system, in that there is a built-in conflict-
of-interest in this interdependence of the 
publisher, journalists in editorial posi-
tions, and the reviewer. In particular, once 
a prestigious investigator has been invited 
by a prestigious journal to write a review, 
the editor-journalists have a vested inter-
est in bringing the article to fruition. The 
invited authors, on the other hand, have a 
unique forum to press their particular agen-
das, to tell the story from their particular 
viewpoint. We are all aware of this situa-
tion, and to the “rewriting of history” by 
some KOLs. Unfortunately for the readers, 
especially those new to the field, it may be 
problematic to trust a particular review 
author’s hidden agenda. Moreover, some 
editor-journalists do not send invited-
reviews out for others to review to ensure 
verity. Without the proper editorial qual-
ity controls in place, the system is subject 
to corruption. A very good discussion of 
the collusion between journalist/editors 
IL-2, the reviewers ignored more than a dec-
ade of reports from numerous investigators 
of T cell mitogenic activities in leukocyte 
conditioned media (Gordon and MacLean, 
1965; Kasakura and Lowenstein, 1965; Bach 
et al., 1970; Dutton et al., 1970; Hoffman 
and Dutton, 1971; Gery and Waksman, 
1972; Gery et al., 1972; Schimpl and Wecker, 
1972; Plate, 1976). Also, by referring to the 
Morgan report as the first description of 
IL-2, the review ignores all of the subse-
quent work in the interleukin field, which 
has now shown that there are multiple mol-
ecules in leukocyte conditioned media with 
TCGF activity (e.g., all of the IL-2Rγ-chain 
cytokines, IL-6, IL-12, and TNFα), and that 
only by identifying each of the molecules is 
it possible to distinguish one from another.
Lymphocyte Activating Factor (LAF), 
a macrophage product shown to be mito-
genic for T cells, was found to be quite 
similar to human leukocytic pyrogen (LP), 
when highly purified LP preparations were 
tested using antigen-specific proliferation 
of macrophage-depleted murine lymph 
node cells (Rosenwasser et al., 1979). The 
development of the defining TCGF bioassay 
(Gillis et al., 1978) allowed the functional 
differentiation of macrophage-derived 
Lymphocyte Activating Factor (LAF) from 
lymphocyte-derived TCGF, and showed 
that LAF is mitogenic for T cells because 
it markedly enhances their production of 
TCGF, which was shown to be the actual T 
cell mitogen in the TCGF bioassay (Smith 
et al., 1980b,c). Collectively, this work then 
served as the scientific rationale for the 
interleukin nomenclature, which was cre-
ated several years after the 1976 Morgan 
article. LAF/LP was termed IL-1 because it 
worked upstream of TCGF, which was given 
the IL-2 designation. However, additional 
work was required to identify and charac-
terize the IL-2 molecule as a 15.5 kDa pro-
tein with a pI = 8.2 (Smith et al., 1980a, 
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In our quest to publish “all the science that 
is fit to read,” we can and should read all of 
the original references that we cite in our 
reviews, and our editorial board should insist 
on accuracy and verity of the citations. This 
will ensure that our Impact Factor is high.
Pertinent to the point, the recent strate-
gic alliance announced between Frontiers 
and Nature Publishing Group (NPG), will 
only serve to underscore the Frontiers com-
mitment to scientific publishing for scien-
tists by scientists. It is to be stressed that 
Frontiers editors, editorial policies, and 
management will continue exactly as before 
the formation of this partnership. Now, 
this alliance will strengthen and extend the 
impact of veritable and verifiable publishing 
by Frontiers. See:
http://www.frontiersin.org/blog/
Nature_Publishing_Group_and_Frontiers_
form_alliance_to_further_open_sci-
ence/226; http://www.frontiersin.org/blog/
Letter_to_the_Frontiers_editors/228
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1981). Furthermore, these IL-2 molecular 
characteristics and the defining IL-2 bio-
assay were instrumental in the successful 
cloning of the IL-2 cDNA by Taniguchi’s 
team (Taniguchi et al., 1983). To underscore 
these points, I referred the editor and the 
authors to two of my recent reviews, which 
detail the chronology of contributions to 
the identification and characterization of 
what we now know as the IL-2 molecule 
(Smith, 2012a,b).
The authors and editors chose to ignore 
my critique and suggestions, and published 
the article with the original wording and 
citation. On the day that the article was pub-
lished, but not before, the editor-journalist 
wrote:
“I am certainly not an expert in this field, 
but I noticed that (another reviewer) wrote 
a review for Nat Rev Immunol in which he 
called out this paper published in 1976 as 
the precedent.”
Thus, as I’ve written before, many for-
profit professional journalists perhaps with 
scientific training, but without the neces-
sary expertise, are making editorial deci-
sions that influence our literature and thus 
our field. In this regard, it should be realized 
and stressed to our colleagues and trainees 
that only journals that are run by scientists 
as editors and peer reviewers and not by 
professional journalists can be trusted for 
the verity and scientific integrity of their 
publications.
The “Silver Lining” of this dark cloud is 
that Frontiers can readily distinguish itself 
from the for-profit closed-access “semi-
scientific magazines” by publishing accu-
rate reviews that are vetted and accepted by 
our scientific peers on our editorial boards. 
We now have 1638 members of our edito-
rial board, and I am proud of the quality of 
their work. If we continue to insist on the 
best scholarship, especially in the reviews 
we publish, Frontiers will be the “go-to site” 
by everyone who wants to rely on the ver-
ity of the content. The for-profit journalist-
editors are handing us the high road on a 
sliver platter by their shoddy journalism. 
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